{
    "clinical_study": {
        "@rank": "164763", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)"
            }, 
            {
                "arm_group_label": "Brexpiprazole up to 1 mg", 
                "arm_group_type": "Experimental", 
                "description": "Brexpiprazole adjunct to open-label treatment with a commercially available ADT"
            }, 
            {
                "arm_group_label": "Brexpiprazole up to 3 mg", 
                "arm_group_type": "Experimental", 
                "description": "Brexpiprazole adjunct to open-label treatment with a commercially available ADT"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly\n      patients with Major Depressive Disorder (MDD)"
        }, 
        "brief_title": "Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment", 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is an outpatient consulting a psychiatrist.\n\n          -  The patient has a recurrent Major Depressive Disorder diagnosed according to\n             DSM-IV-TR\u2122. The current Major Depressive Episode (MDE) should be confirmed using the\n             Mini International Neuropsychiatric Interview (MINI).\n\n          -  The patient had at least one previous MDE before the age of 60 years.\n\n          -  The patient has a moderate to severe depression and an insufficient response to at\n             least one and no more than three adequate antidepressants treatments.\n\n          -  The patient, if a woman, must have had her last natural menstruation \u226524 months prior\n             to the Screening Visit.\n\n          -  The patient, if a man, agrees to protocol-defined use of effective contraception if\n             his female partner is of childbearing potential.\n\n        Exclusion Criteria:\n\n          -  The patient has any current psychiatric disorder or Axis I disorder (DSM-IV-TR\u2122\n             criteria), established as the primary diagnosis, other than MDD.\n\n          -  The patient has a current Axis II (DSM-IV-TR\u2122) diagnosis of borderline, antisocial,\n             paranoid, schizoid, schizotypical or histrionic personality disorder.\n\n          -  The patient has experienced/experiences hallucinations, delusions or any psychotic\n             symptomatology in the current MDE.\n\n          -  The patient suffers from mental retardation, organic mental disorders, or mental\n             disorders due to a general medical condition (DSM-IV-TR\u2122 criteria).\n\n          -  The patient, in the opinion of the investigator, or according to Columbia Suicide\n             Severity Rating Scale (C-SSRS), is at significant risk of suicide.\n\n          -  The patient has had neuroleptic malignant syndrome.\n\n          -  The patient has any relevant medical history or currrent presence of systemic\n             disease.\n\n          -  The patient has a neurodegenerative disorder.\n\n          -  The patient has, at the Screening Visit an abnormal ECG that is, in the\n             investigator's opinion, clinically significant.\n\n          -  The patient has a history of cancer, other than basal cell or Stage 1 squamous cell\n             carcinoma of the skin, that has not been in remission for >5 years prior to the first\n             dose of IMP.\n\n          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol\n             or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "1334", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837797", 
            "org_study_id": "14571A", 
            "secondary_id": "2012-001361-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Once daily, tablets, orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Brexpiprazole up to 1 mg", 
                    "Brexpiprazole up to 3 mg"
                ], 
                "description": "once daily dose, tablets, orally", 
                "intervention_name": "Brexpiprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antidepressive Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "National City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91950"
                    }, 
                    "name": "US001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "US008"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score", 
            "measure": "Change from randomisation in depressive symptoms during the randomised treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to 20 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837797"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical Global Impression - Severity of Illness (CGI-S) score", 
                "measure": "Change from randomisation in global clinical impression during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Sheehan Disability Scale (SDS) total score", 
                "measure": "Change from randomisation in functionality assessed by SDS during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Social Adaptation Self-evaluation Scale (SASS) total score", 
                "measure": "Change from randomisation in social adaptation during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Based on pre-specified decrease in MADRS total score", 
                "measure": "Response during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Based on pre-specified decrease in MADRS total score", 
                "measure": "Sustained response during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Based on a pre-specified MADRS total score", 
                "measure": "Remission during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Based on pre-specified MADRS total score", 
                "measure": "Sustained remission during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 weeks"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 weeks and a 4-week safety follow up"
            }, 
            {
                "description": "Columbia Suicide Severity Rating Scale (eC-SSRS) score", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 weeks"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}